The instant disclosure provides antibodies that specifically bind to CD73 (e.g., human CD73) and antagonize CD73 function. Also provided are anti-CD73 antibodies that further comprise a TGFβ-binding moiety or a VEGF-binding moiety. The instant disclosure additionally provides pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy.

The present invention provides anti-CLDN18.2 antibody-drug conjugates which are effective for treating and/or preventing cancer diseases associated with cells expressing CLDN18.2, including gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.

Provided is an antibody for treating a cancer, more specifically, an anti-CD43 antibody binding to an extracellular domain of CD43, compositions for treating a cancer or inhibiting a cancer stem cell comprising the antibody as an active ingredient, and methods for screening an agent of inhibiting a cancer stem cell.

The present invention generally relates to antibodies that bind to GPRC5D, including bispecific antigen binding molecules e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

Provided is a binding molecule specifically for CD39 and the use thereof. Specifically, provided is an antibody that binds to CD39 and inhibits the activity of CD39 or an antigen binding part thereof, the use of the antibody or the antigen binding part thereof in the treatment of diseases, a nucleic acid molecule encoding the antibody or the antigen binding part thereof, an expression vector for expressing the antibody or the antigen binding part thereof, a host cell, and a preparation method.

Provided is a separated antigen binding protein, containing at least one CDR in VH with the amino acid sequence as shown in SEQ ID NO: 1 or SEQ ID NO: 46; and at least one CDR in VL with the amino acid sequence as shown in SEQ ID NO: 2. Also provided are an immunoconjugate containing the separated antigen binding protein, nucleic acid coding the separated antigen binding protein, a carrier containing the separated antigen binding protein, a cell containing the nucleic acid or the carrier, a method for preparing the separated antigen binding protein, and use of the separated antigen binding protein.

Disclosed herein are methods and compositions for disrupting an interaction between Galectin-3 and insulin receptor or glucose transporters. Further disclosed herein are methods and compositions for the treatment of a disease or a disorder in a subject, such as the treatment of diabetes mellitus, insulin resistance, chronic hyperinsulinemia, dysmetabolic syndrome, type A insulin resistance syndrome, type B insulin resistance syndrome, gestational diabetes, acanthosis nigricans, polycystic ovary syndrome (PCOS), obesity, muscle wasting, cardiovascular diseases, cardiac hypertrophy, myocardial ischemia, hypertension, pancreatic cancer associated diabetes (PCDM), rhabdomyosarcoma, or cancers.

Antibodies and antibody-drug conjugates that selectively bind to a membrane-associated extracellular portion of a cleaved amphiregulin precursor protein; methods of using the antibodies and antibody-drug conjugates to detect and inhibit the growth of neoplastic cells; pharmaceutical compositions containing the antibodies and/or antibody-drug conjugates as the active ingredient(s); kits containing the antibodies and/or antibody-drug conjugates.

Therapeutic antibodies having binding specificity for ROR-1 expressed on cancer cells (particularly leukemic and lymphomic cells) and pharmaceutical compositions containing one or more such antibodies for use in treating cancer. Methods for diagnosing such cancers through in vitro detection of binding to ROR-1 protein expressed on putative cancer cells are also provided.